Which has the lower trailing P/E, RMD or TEVA?

RMD has the lower trailing P/E: RMD trades at 22.67 and TEVA at 62.70. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, RMD or TEVA?

Over the past five years, RMD grew revenue faster — RMD at a 12.08% CAGR versus TEVA at 1.19%.

Does RMD or TEVA pay a bigger dividend?

RMD pays a dividend (1.02% yield), while TEVA is a former payer with no current dividend run rate.

Is RMD or TEVA more profitable?

RMD runs the higher net margin — RMD at 26.94% versus TEVA at 4.08%.

How have RMD and TEVA total returns compared?

Over the past 10 years, RMD delivered 14.33% and TEVA delivered -2.70% annualized total return. Past performance doesn't predict future results.

ResMed Inc. (RMD) vs Teva Pharmaceutical Industries Limited (TEVA)

A side-by-side comparison of ResMed Inc. and Teva Pharmaceutical Industries Limited across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 28, 2026. Differences are shown without an overall score or investment verdict.

RMD

ResMed Inc.

$34.61B

$238.59HealthcareDelayed quote: Aug 28, 2026, 12:20 PM EDT

TEVA

Teva Pharmaceutical Industries Limited

$42.66B

$36.63HealthcareDelayed quote: Aug 28, 2026, 12:20 PM EDT

Total return — RMD vs TEVA

growth of $100 · dividends reinvested · last 10y

RMD +293.0% (+14.7%/yr)TEVA -23.4% (-2.6%/yr)RMD compounded faster over this window

Log scale — wide-divergence pair

RMD TEVA

RMD vs TEVA: by the numbers

•TEVA is the larger company ($42.66B vs $34.61B market cap).
•RMD trades at the lower trailing earnings multiple (22.67 vs 62.70 P/E), one valuation lens rather than an overall verdict.
•RMD converts more revenue to profit (26.94% vs 4.08% net margin).
•RMD grew revenue faster over the past five years (12.08% vs 1.19% CAGR).
•RMD pays a dividend (1.02% yield), while TEVA is a former payer with no current dividend run rate.

Metrics side by side

Valuation

Metric	RMD	TEVA
P/E ratio	22.67	62.70
Forward P/E	21.19	18.80
P/S ratio	6.05	2.57
P/B ratio	5.19	5.73
EV / EBITDA	16.04	19.40
FCF yield	4.84%	3.03%

Profitability

Metric	RMD	TEVA
Gross margin	61.16%	52.47%
Operating margin	33.48%	11.45%
Net margin	26.94%	4.08%
ROE	23.13%	9.10%
ROIC	19.18%	6.79%

Dividends

Metric	RMD	TEVA
Dividend yield	1.02%	N/A
Payout ratio	22.99%	N/A

Growth (annualized)

Metric	RMD	TEVA
Revenue CAGR (5Y)	12.08%	1.19%
EPS CAGR (5Y)	26.14%	N/A
FCF CAGR (5Y)	21.62%	14.58%
Total return CAGR (5Y)	-2.97%	32.11%

Frequently asked

Which has the lower trailing P/E, RMD or TEVA?: RMD has the lower trailing P/E: RMD trades at 22.67 and TEVA at 62.70. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, RMD or TEVA?: Over the past five years, RMD grew revenue faster — RMD at a 12.08% CAGR versus TEVA at 1.19%.
Does RMD or TEVA pay a bigger dividend?: RMD pays a dividend (1.02% yield), while TEVA is a former payer with no current dividend run rate.
Is RMD or TEVA more profitable?: RMD runs the higher net margin — RMD at 26.94% versus TEVA at 4.08%.
How have RMD and TEVA total returns compared?: Over the past 10 years, RMD delivered 14.33% and TEVA delivered -2.70% annualized total return. Past performance doesn't predict future results.

Go deeper

Full RMD analysis Full TEVA analysis Interactive comparison tool

Dig into the metrics

ResMed P/E ratio Teva Pharmaceutical Industries P/E ratio ResMed dividend yield ResMed ROE Teva Pharmaceutical Industries ROE ResMed operating margin Teva Pharmaceutical Industries operating margin ResMed revenue growth Teva Pharmaceutical Industries revenue growth ResMed free cash flow Teva Pharmaceutical Industries free cash flow

ResMed & Teva Pharmaceutical Industries appear in these rankings

Highest ROIC Stocks Highest Operating Margin Stocks Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 28, 2026.